(5) Fair Value Measurements
The Company’s cash, cash equivalents and
marketable securities are stated at fair value. The carrying value of accounts receivable, other current assets, accrued expenses, and accounts payable approximates fair market value because of the short maturity of these financial
instruments.
The Company’s cash equivalents are generally
classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
All held-to-maturity securities as of September 30, 2023 were US Treasury and federal bonds. Investments in these bonds are based
on quoted market prices in active markets, and are included in the Level 1 fair value hierarchy.
The tables below set forth the Company’s cash
and cash equivalents, as well as marketable securities as of September 30, 2023 and December 31, 2022, respectively, which are measured at fair value on a recurring basis by level within the fair value hierarchy.
|
|
September 30, 2023
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
11,088,033
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
11,088,033
|
|
Held-to-maturity securities
|
|
|
4,143,863 |
|
|
|
- |
|
|
|
- |
|
|
|
4,143,863 |
|
|
|
$
|
15,231,896 |
|
|
$
|
- |
|
|
$
|
- |
|
|
$
|
15,231,896 |
|
|
|
December 31, 2022
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
9,866,628
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
9,866,628
|
|
Held-to-maturity securities |
|
|
4,028,565 |
|
|
|
- |
|
|
|
- |
|
|
|
4,028,565 |
|
|
|
$
|
13,895,193 |
|
|
$
|
- |
|
|
$
|
- |
|
|
$
|
13,895,193 |
|
The Company did not hold financial assets and liabilities which were recorded at fair value in the Level 2 or 3 categories as of
September 30, 2023.
The preceding methods may produce a fair value calculation that may not be indicative of net realizable value or reflective of
future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of
certain financial instruments could result in a different fair value measurement at the reporting date.
|